| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $391,282,297 | 59 | 100 |
| Riva Alessandro | director | 0 | $0 | 1 | $65,617 | $-65,617 |
| Dugan Margaret | director | 0 | $0 | 1 | $65,636 | $-65,636 |
| Ball Titus B. | Principal Accounting Officer | 0 | $0 | 3 | $127,341 | $-127,341 |
| BAKER BROS. ADVISORS LP | director | 0 | $0 | 1 | $261,981 | $-261,981 |
| Rosenberg Aaron | Chief Financial Officer | 0 | $0 | 2 | $524,448 | $-524,448 |
| Sanders Corazon (Corsee) D. | director | 0 | $0 | 2 | $961,167 | $-961,167 |
| Wang Lai | President, Global Head of R&D | 0 | $0 | 4 | $1.17M | $-1.17M |
| Lee Chan Henry | SVP, General Counsel | 0 | $0 | 16 | $4.63M | $-4.63M |
| Wu Xiaobin | President and COO | 0 | $0 | 8 | $8.75M | $-8.75M |
| Wang Xiaodong | Chair, Scientific Advisory Brd | 0 | $0 | 4 | $46.84M | $-46.84M |
| OYLER JOHN | Chief Executive Officer | 0 | $0 | 17 | $327.88M | $-327.88M |
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients …
Over the last 12 months, insiders at BeOne Medicines AG have bought $0 and sold $391.28M worth of BeOne Medicines AG stock.
On average, over the past 5 years, insiders at BeOne Medicines AG have bought $0 and sold $328.98M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-27 | Sale | Wang Xiaodong | Chair, Scientific Advisory Brd | 31,028 0.0288% | $362.97 | $11.26M | +1.17% | |
| 2026-10-13 | Sale | Wang Xiaodong | Chair, Scientific Advisory Brd | 31,027 0.0292% | $350.99 | $10.89M | +6.24% | |
| 2026-09-30 | Sale | Lee Chan Henry | SVP, General Counsel | 1,115 0.0011% | $375.00 | $418,125 | -0.25% | |
| 2026-09-28 | Sale | Wang Xiaodong | Chair, Scientific Advisory Brd | 31,028 0.0276% | $364.79 | $11.32M | -0.38% | |
| 2026-09-08 | Sale | Wang Xiaodong | Chair, Scientific Advisory Brd | 38,287 0.0341% | $349.10 | $13.37M | +3.05% | |
| 2026-09-01 | Sale | Ball Titus B. | Principal Accounting Officer | 132 0.0001% | $355.86 | $46,974 | +0.85% | |
| 2026-08-25 | Sale | Wu Xiaobin | President and COO | 280 0.0003% | $380.00 | $106,400 | -3.88% | |
| 2026-08-12 | Sale | OYLER JOHN | Chief Executive Officer | 54,892 0.0512% | $358.15 | $19.66M | +1.02% | |
| 2026-08-11 | Sale | OYLER JOHN | Chief Executive Officer | 70,907 0.0668% | $361.90 | $25.66M | +0.95% | |
| 2026-08-11 | Sale | Lee Chan Henry | SVP, General Counsel | 2,666 0.0025% | $360.00 | $959,760 | +0.95% | |
| 2026-08-10 | Sale | OYLER JOHN | Chief Executive Officer | 115,011 0.1028% | $357.87 | $41.16M | +1.00% | |
| 2026-08-03 | Sale | Rosenberg Aaron | Chief Financial Officer | 1,157 0.001% | $312.71 | $361,811 | +15.26% | |
| 2026-07-30 | Sale | Lee Chan Henry | SVP, General Counsel | 1,044 0.0009% | $323.69 | $337,932 | +12.17% | |
| 2026-07-22 | Sale | Lee Chan Henry | SVP, General Counsel | 1,669 0.0016% | $325.00 | $542,425 | +12.39% | |
| 2026-07-21 | Sale | OYLER JOHN | Chief Executive Officer | 61,397 0.0573% | $317.67 | $19.5M | +12.78% | |
| 2026-07-20 | Sale | OYLER JOHN | Chief Executive Officer | 48,316 0.0455% | $312.25 | $15.09M | +15.68% | |
| 2026-07-17 | Sale | OYLER JOHN | Chief Executive Officer | 64,628 0.0594% | $312.00 | $20.16M | +15.11% | |
| 2026-07-16 | Sale | OYLER JOHN | Chief Executive Officer | 166,597 0.1562% | $318.09 | $52.99M | +13.12% | |
| 2026-07-15 | Sale | OYLER JOHN | Chief Executive Officer | 116,557 0.1093% | $311.94 | $36.36M | +15.35% | |
| 2026-07-14 | Sale | OYLER JOHN | Chief Executive Officer | 145,861 0.1374% | $305.95 | $44.63M | +17.11% |
| Increased Positions | 174 | +67.18% | 2M | +6.66% |
| Decreased Positions | 109 | -42.08% | 1M | -3.91% |
| New Positions | 60 | New | 351,665 | New |
| Sold Out Positions | 38 | Sold Out | 143,997 | Sold Out |
| Total Postitions | 324 | +25.1% | 34M | +2.75% |